CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2020

Primary Completion Date

November 15, 2023

Study Completion Date

November 15, 2026

Conditions

Relapsed and/or Refractory Acute Lymphoblastic LeukemiaRelapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG

CD79b CAR-T Cells

Each subject receive CD79b CAR-Tcells by intravenous infusion

Trial Locations (1)

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER